Pirfenidone: A Novel Potential Therapeutic Agent in the Management of Chronic Allograft Rejection

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2153-2156

  Dosanjh, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; PIRFENIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; FIBROSIS; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; LIVER FIBROSIS; LUNG TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; ORGAN TRANSPLANTATION; PATHOGENESIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; REPERFUSION INJURY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; GRAFT REJECTION; HUMANS; LUNG TRANSPLANTATION; PULMONARY FIBROSIS; PYRIDONES; REPERFUSION INJURY;

EID: 34548695198     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.07.078     Document Type: Article

References (28)

1. Nakazato H., Oku H., Yamane S., et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 446 (2002) 177
2. Piecyk M., Wax S., Beck A., et al. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J 19 (2000) 4154
3. Giri S.N., Leonard S., Shi X., et al. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18 (1999) 169
4. Liu H., Drew P., Cheng Y., et al. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J Thorac Cardiovasc Surg 130 (2005) 852
5. Dosanjh A.K., Wan B., Throndset W., et al. Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 30 (1998) 1910
6. Dosanjh A., Ikonen T., Wan B., et al. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 15 (2002) 433
7. Hewitson T.D., Kelynack K.J., Tait M.G., et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14 (2001) 453
8. Arumugum T., Shiels I., Margolin S., et al. Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine. Clin Exp Pharmacol Physiol 29 (2002) 996
9. Kaibori M., Yanagida H., Uchida Y., et al. Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. Transplant Proc 36 (2004) 1973
10. Kaibori M., Yanagida H., Yokoigawa A., et al. Effect of pirfenidone on induction of chemokines in rat hepatocytes. Transplant Proc 36 (2004) 1980
11. Iyer S.N., Margolin S.B., Hyde D.M., et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Lung Res 24 (1998) 119
12. Brightbill H.D., PLevy S.E., Modlin R.L., et al. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 164 (2000) 1940
13. Mirkovic S., Seymour A., and Fenning A. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135 (2002) 961
14. Tada S., Nakamura M., Enjoi M., et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 28 (2001) 522
15. Lasky J. Pirfenidone. IDrugs 7 (2004) 166
16. Garcia L., Hernandez I., Sandoval A., et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37 (2002) 797
17. Raghu G., Johnson W.C., Lockhart D., et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. AJRCCM 159 (1999) 1061
18. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040
19. Gahl W.A., Brantly M., Troendle J., et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76 (2002) 234
20. Babovic D., Ballman K., Michels V., et al. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 68 (2006) 1860
21. To Y., Sano Y., Sekiya T., et al. Successful treatment of steroid-resistant bronchiolitis obliterans-organizing pneumonia with orally administered cyclosporin and pirfenidone. Nihon Kokyuki Gakkai zasshi 38 (2000) 24
22. Dosanjh A. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol 536 (2006) 219
23. McKane B.W., Fernandez F., Narayanan K., et al. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Transplantation 77 (2006) 664
24. Zhou H., Latham C.W., Zander D.S., et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant 24 (2005) 1577
25. Liu H., Drew P., Gaugher A.C., et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 5 (2005) 1256
26. Shihab F.S., Bennett W.M., Yi H., et al. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 79 (2005) 419
27. Brook N.R., Waller J.R., Bicknell G.R., et al. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc 3 (2005) 130
28. Brook N.R., Waller J.R., Bicknell G.R., et al. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 125 (2005) 137